MedTrace Logo

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

NCT01054079 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-07-05

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer

Interventions

OTHER

laboratory biomarker analysis

Correlative study

PROCEDURE

quality-of-life assessment

Ancillary study

OTHER

questionnaire administration

Ancillary study

DRUG

cinacalcet hydrochloride

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • K.C. Balaji, MD · Wake Forest University Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-08-31
Completion
2014-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054079 on ClinicalTrials.gov